Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2023; 15(03): 354-360
DOI: 10.1055/s-0043-1761925
Original Article

Stromal Expression of CD10 in Breast Carcinoma and Its Association with Known Prognostic Factors—A Tissue Microarray-Based Study

Nidha Gaffoor
1   Department of Pathology, Dr. Chandramma Dayananda Sagar Institution of Medical Education and Research, Ramanagara, Karnataka, India
,
Jayashree Krishnamurthy
2   Department of Pathology, JSS Medical College, Mysuru, Karnataka, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Background Breast cancer is an epithelial malignancy; however, stroma plays a key role with its stimulatory and inhibitory factors in modulating tumor invasion and metastasis. CD10, a matrix metalloproteinase, is known to regulate cell adhesion, migration and helps in determining the progression of tumor. This knowledge helps to identify specific signals that promote growth, dedifferentiation, invasion, metastasis and serve as target for better therapeutic management.

Objectives The aim of this study was to estimate frequency of expression of stromal CD10 and assess its prognostic significance in breast carcinomas by correlating with known prognostic factors.

Materials and Methods Morphological parameters of 62 cases of carcinoma breast were studied on H&E (hematoxylin and eosin) stained sections and expressions of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2/neu), and CD10 on manually constructed tissue microarray sections by immunohistochemistry (IHC). Staining pattern, percentage of stained cells, and intensity of stains were evaluated and IHC scoring of all markers was done. CD10 scores were correlated with the known prognostic factors (ER, PR, and HER2/neu). A p-value less than 0.05 was considered as significant.

Results Stromal expression of CD10 was found in 82.3% of cases and it was significantly associated with increasing tumor size (p = 0.012), increasing tumor grade (p = 0.001), lymph node metastasis (p = 0.018), necrosis (p = 0.008), lymphovascular invasion (p = 0.008), ER negativity (p = 0.001), PR negativity(p = 0.007), HER 2 positivity (p = 0.012), triple-negative molecular subtypes (p = 0.001), and poor prognostic groups (p = 0.01).

Conclusion CD10 can be used as an independent prognostic stromal marker and this will help to envisage new therapeutic strategies.

Keywords

breast - carcinoma - immunohistochemistry - prognosis

Authors' Contributions

N.G. contributed to literature search, clinical and experimental studies, data acquisition, data and statistical analysis, and manuscript preparation. J.K. helped in conceptualization, designing, definition of intellectual content, and manuscript editing and review. N.G. has provided guarantee.


Funding

None.




Publication History

Article published online:
24 February 2023

© 2023. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Kamath R, Mahajan KS, Ashok L, Sanal TS. A study on risk factors of breast cancer among patients attending the tertiary care hospital, in Udupi district. Indian J Community Med 2013; 38 (02) 95-99
    CrossrefPubMedGoogle Scholar
  • 2 Jana SH, Jha BM, Patel C, Jana D, Agarwal A. CD10-a new prognostic stromal marker in breast carcinoma, its utility, limitations and role in breast cancer pathogenesis. Indian J Pathol Microbiol 2014; 57 (04) 530-536
    CrossrefPubMedGoogle Scholar
  • 3 Puri V, Jain M, Thomas S. Stromal expression of CD10 in invasive breast carcinoma and its correlation with ER, PR, HER2-neu, and Ki67. Int J Breast Cancer 2011; 2011: 437957
    CrossrefPubMedGoogle Scholar
  • 4 Taghizadeh-Kermani A, Jafarian AH, Ashabyamin R. et al. The stromal overexpression of CD10 in invasive breast cancer and its association with clinicopathologic factors. Iran J Cancer Prev 2014; 7 (01) 17-21
    PubMedGoogle Scholar
  • 5 Mohammadizadeh F, Salavati M, Moghaddam NA. CD10 expression in stromal component of invasive breast carcinoma: a potential prognostic determinant. J Res Med Sci 2012; 17 (02) 194-199
    Google Scholar
  • 6 Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3 (06) 453-458
    CrossrefPubMedGoogle Scholar
  • 7 Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol 2007; 20 (01) 84-89
    CrossrefPubMedGoogle Scholar
  • 8 Thomas S, Babu RJ, Agarwal K. et al. Effect of neoadjuvant chemotherapy on stromal CD10 antigens in breast cancer - a preliminary study. Indian J Cancer 2013; 50 (01) 46-51
    CrossrefPubMedGoogle Scholar
  • 9 Tse GM, Tsang AK, Putti TC. et al. Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. J Clin Pathol 2005; 58 (02) 185-189
    CrossrefPubMedGoogle Scholar
  • 10 Moritani S, Kushima R, Sugihara H, Bamba M, Kobayashi TK, Hattori T. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol 2002; 15 (04) 397-405
    CrossrefPubMedGoogle Scholar
  • 11 Albrecht M, Gillen S, Wilhelm B, Doroszewicz J, Aumüller G. Expression, localization and activity of neutral endopeptidase in cultured cells of benign prostatic hyperplasia and prostate cancer. J Urol 2002; 168 (01) 336-342
    CrossrefPubMedGoogle Scholar
  • 12 Ogawa H, Iwaya K, Izumi M. et al. Expression of CD10 by stromal cells during colorectal tumor development. Hum Pathol 2002; 33 (08) 806-811
    CrossrefPubMedGoogle Scholar
  • 13 Braham H, Trimeche M, Ziadi S. et al. CD10 expression by fusiform stromal cells in nasopharyngeal carcinoma correlates with tumor progression. Virchows Arch 2006; 449 (02) 220-224
    CrossrefPubMedGoogle Scholar
  • 14 Rosai J, Ackerman L. Rosai and Ackerman's Surgical Pathology. 10th ed.. Edinburgh: Mosby Elsevier; 2011: 1681-1718
    Google Scholar
  • 15 Amin MB, Edge S, Greene F. et al, Eds. AJCC Cancer Staging Manual. 8th ed.. Chicago, USA: Springer International Publishing; 2017. 17(6):1471–4
    CrossrefGoogle Scholar
  • 16 Blamey RW, Ellis IO, Pinder SE. et al. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer 2007; 43 (10) 1548-1555
    CrossrefPubMedGoogle Scholar
  • 17 Kim HS, Kim GY, Kim YW, Park YK, Song JY, Lim SJ. Stromal CD10 expression and relationship to the E-cadherin/β-catenin complex in breast carcinoma. Histopathology 2010; 56 (06) 708-719
    CrossrefPubMedGoogle Scholar
  • 18 Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000; 80 (12) 1943-1949
    CrossrefPubMedGoogle Scholar
  • 19 Kampf C, Olsson I, Ryberg U, Sjöstedt E, Pontén F. Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas. J Vis Exp 2012; (63) 3620
    PubMedGoogle Scholar
  • 20 Tripathi M, Billet S, Bhowmick NA. Understanding the role of stromal fibroblasts in cancer progression. Cell Adhes Migr 2012; 6 (03) 231-235
    CrossrefPubMedGoogle Scholar
  • 21 Fitzgibbons PL, Page DL, Weaver D. et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124 (07) 966-978
    PubMedGoogle Scholar
  • 22 Michaelson JS, Silverstein M, Sgroi D. et al. The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer 2003; 98 (10) 2133-2143
    CrossrefPubMedGoogle Scholar
  • 23 Vo TN, Mekata E, Umeda T. et al. Prognostic impact of CD10 expression in clinical outcome of invasive breast carcinoma. Breast Cancer 2015; 22 (02) 117-128
    CrossrefPubMedGoogle Scholar
  • 24 Iwaya K, Ogawa H, Izumi M, Kuroda M, Mukai K. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. Virchows Arch 2002; 440 (06) 589-593
    CrossrefPubMedGoogle Scholar
  • 25 Arora G, Girdhar M, Baghla A, Lajpal K, Manjari M, Jagga K. Comparing the expression of myoepithelial cell markers CD10 and smooth muscle actin with the estrogen receptor status in the invasive carcinoma breast: An immunohistochemical study. Clin Cancer Investig J 2013; 2 (01) 20-24
    CrossrefGoogle Scholar
  • 26 Bremnes RM, Dønnem T, Al-Saad S. et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol 2011; 6 (01) 209-217
    CrossrefPubMedGoogle Scholar
  • 27 Gilchrist KW, Gray R, Fowble B, Tormey DC, Taylor IV SG. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. J Clin Oncol 1993; 11 (10) 1929-1935
    CrossrefPubMedGoogle Scholar
  • 28 Rakha EA, Martin S, Lee AH. et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer 2012; 118 (15) 3670-3680
    CrossrefPubMedGoogle Scholar